Please Scroll Down to See Forums Below 
Noopept
From Wikipedia, the free encyclopedia
Noopept
Noopept.svg
Systematic (IUPAC) name
N-Phenylacetyl-L-prolylglycine ethyl ester
Clinical data
Legal status Unscheduled (US)
Identifiers
CAS number 157115-85-0 Yes
ATC code ?
PubChem CID 180496
ChemSpider 157065
Chemical data
Formula C17H22N2O4
Mol. mass 318.367 g/mol
SMILES[show]
InChI[show]
(what is this?) (verify)
Noopept (Russian: Ноопепт; GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. The compound is patented in both the US and Russia with patent of Russian Federation number 2119496, US Patent number 5,439,930 issued 8/8/1995.[1] It is sold as a dietary supplement in the US and as a medicine in other countries.
Mechanism of action[edit]
This section needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the section and add the appropriate references if you can. Unsourced or poorly sourced material may be removed. (November 2012)
Rod of asclepius.png
It is derived from the racetam family of drugs and shares similar mechanisms of action,[2][3] but is, according to studies, 1000 times more potent than the prototypical racetam drug, piracetam.[4] Animal studies have shown noopept to be neuroprotective and enhance memory in various tests.[5][6][7][8][9] Since it is a peptide-derived compound, noopept is degraded by enzymes in the GI tract and liver. Its oral bioavailability has been shown to be much lower than other routes of administration, with serum concentrations reaching 10% of IV levels per-orally.[10][not in citation given (See discussion.)] It does show good blood–brain barrier penetration[11] in rats (although a previous study concluded that "GVS-111 itself was not found in rat brain 1 h after 5 mg/kg i.p. administration up to limit of detection" and that administration of Noopept only increases the concentration of endogenous nootropic cyclo-L-prolylglycine[3]), and human studies have shown promising results, with potential application in the treatment of Alzheimer's disease.[12] It is also an "immunocorrector" in mice.[13]
It has been found to stimulate the expression of NGF and BDNF in rat hippocampus.[8] Expression of the studied neurotropic factors in the cerebral cortex was below the control after single administration of Noopept, while chronic administration caused a slight increase in BDNF expression. In the hippocampus, expression of mRNA for both neurotrophins increased after acute administration of Noopept. Chronic treatment with Noopept was not followed by the development of tolerance, but even potentiated the neurotrophic effect.[8]
Product information[edit]
Noopept Box Front
Noopept blister pack
In Russia, Noopept is considered a nootropic drug with neuroprotective properties. It is reported to improve learning ability and memory (including the initial processing of information, consolidation, and retrieval).[medical citation needed] It is also used to prevent the development of amnesia induced by electroshock.[14][unreliable medical source?][15][unreliable medical source?]
In animal studies, Noopept helped to restore memory and other cognitive functions disturbed as a result of ischemia as well as damage due to hypoxia (a condition in which the body or region of the body is deprived of adequate oxygen supply).[16] The therapeutic effect of the drug in patients with organic disorders of the central nervous system appeared within 5-7 days of treatment. Also reported was the reduction or disappearance of anxiety, irritability, emotional lability and sleep disorders.[14][unreliable medical source?][15][unreliable medical source?]
It has also been observed to reverse and prevent learned helplessness neurosis in rats after long term (21 day) treatment.[17]
From Wikipedia, the free encyclopedia
Noopept
Noopept.svg
Systematic (IUPAC) name
N-Phenylacetyl-L-prolylglycine ethyl ester
Clinical data
Legal status Unscheduled (US)
Identifiers
CAS number 157115-85-0 Yes
ATC code ?
PubChem CID 180496
ChemSpider 157065
Chemical data
Formula C17H22N2O4
Mol. mass 318.367 g/mol
SMILES[show]
InChI[show]
(what is this?) (verify)
Noopept (Russian: Ноопепт; GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. The compound is patented in both the US and Russia with patent of Russian Federation number 2119496, US Patent number 5,439,930 issued 8/8/1995.[1] It is sold as a dietary supplement in the US and as a medicine in other countries.
Mechanism of action[edit]
This section needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the section and add the appropriate references if you can. Unsourced or poorly sourced material may be removed. (November 2012)
Rod of asclepius.png
It is derived from the racetam family of drugs and shares similar mechanisms of action,[2][3] but is, according to studies, 1000 times more potent than the prototypical racetam drug, piracetam.[4] Animal studies have shown noopept to be neuroprotective and enhance memory in various tests.[5][6][7][8][9] Since it is a peptide-derived compound, noopept is degraded by enzymes in the GI tract and liver. Its oral bioavailability has been shown to be much lower than other routes of administration, with serum concentrations reaching 10% of IV levels per-orally.[10][not in citation given (See discussion.)] It does show good blood–brain barrier penetration[11] in rats (although a previous study concluded that "GVS-111 itself was not found in rat brain 1 h after 5 mg/kg i.p. administration up to limit of detection" and that administration of Noopept only increases the concentration of endogenous nootropic cyclo-L-prolylglycine[3]), and human studies have shown promising results, with potential application in the treatment of Alzheimer's disease.[12] It is also an "immunocorrector" in mice.[13]
It has been found to stimulate the expression of NGF and BDNF in rat hippocampus.[8] Expression of the studied neurotropic factors in the cerebral cortex was below the control after single administration of Noopept, while chronic administration caused a slight increase in BDNF expression. In the hippocampus, expression of mRNA for both neurotrophins increased after acute administration of Noopept. Chronic treatment with Noopept was not followed by the development of tolerance, but even potentiated the neurotrophic effect.[8]
Product information[edit]
Noopept Box Front
Noopept blister pack
In Russia, Noopept is considered a nootropic drug with neuroprotective properties. It is reported to improve learning ability and memory (including the initial processing of information, consolidation, and retrieval).[medical citation needed] It is also used to prevent the development of amnesia induced by electroshock.[14][unreliable medical source?][15][unreliable medical source?]
In animal studies, Noopept helped to restore memory and other cognitive functions disturbed as a result of ischemia as well as damage due to hypoxia (a condition in which the body or region of the body is deprived of adequate oxygen supply).[16] The therapeutic effect of the drug in patients with organic disorders of the central nervous system appeared within 5-7 days of treatment. Also reported was the reduction or disappearance of anxiety, irritability, emotional lability and sleep disorders.[14][unreliable medical source?][15][unreliable medical source?]
It has also been observed to reverse and prevent learned helplessness neurosis in rats after long term (21 day) treatment.[17]
